利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.017 秒)

    Method
    4.
    发明申请
    Method 审中-公开
    方法

    公开(公告)号：US20080038228A1

    公开(公告)日：2008-02-14

    申请号：US10571992

    申请日：2004-09-24

    申请人： Nina Rautonen ,  Jussi Nurmi ,  Paivi Nurminen ,  Pauli Puolakkainen

    发明人： Nina Rautonen ,  Jussi Nurmi ,  Paivi Nurminen ,  Pauli Puolakkainen

    IPC分类号： A61K35/74 ,  A61K31/205 ,  A61P29/00 ,  A61K35/66

    CPC分类号： A61K35/745 ,  A23K10/16 ,  A23K10/18 ,  A23K50/75 ,  A61K31/19 ,  A61K31/205 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention relates to the use of a microorganism and/or a metabolite thereof to at least increase the amount of a COX-1 mRNA in a cell. The present invention further relates to the use of a microorganism and/or a metabolite thereof in the manufacture of a medicament to treat the side effects associated with nonsteroidal antiinflammatory drugs (NSAIDs). The present invention further relates to a pharmaceutical preparation comprising in combination a nonsteroidal antiinflammatory drug (NSAIDs) and a microorganism and/or a metabolite thereof which is capable of at least increasing the amount of a COX-1 mRNA in a cell. The present invention yet further relates to a pharmaceutical preparation comprising in combination betaine or a pharmaceutically acceptable salt thereof and a microorganism and/or a metabolite thereof which is capable of at least increasing the amount of a COX-1 mRNA in a cell. The microorganism may suitably be a bacterium, preferably from the genus Bifidobacterium.

    摘要翻译： 本发明涉及使微生物和/或其代谢物至少增加细胞中COX-1mRNA的量的用途。 本发明还涉及微生物和/或其代谢物在制备用于治疗与非甾体抗炎药（NSAID）相关的副作用的药物中的用途。 本发明还涉及一种药物制剂，其包含非甾体抗炎药（NSAID）和能够至少增加细胞中COX-1 mRNA的量的微生物和/或其代谢物的组合。 本发明还涉及包含组合甜菜碱或其药学上可接受的盐和能够至少增加细胞中COX-1 mRNA的量的微生物和/或其代谢物的药物制剂。 微生物可以适当地是细菌，优选来自双歧杆菌属。

    Method for modulating satiety signaling with specific strains of Lactobacillus acidophilus and Bacillus
    5.
    发明授权
    Method for modulating satiety signaling with specific strains of Lactobacillus acidophilus and Bacillus 有权
    用嗜酸乳杆菌和芽孢杆菌特异性菌株调节饱腹感信号的方法

    公开(公告)号：US08257695B2

    公开(公告)日：2012-09-04

    申请号：US12162160

    申请日：2007-01-28

    申请人： Nina Rautonen ,  Heli Putaala ,  Arthur Ouwehand ,  Kirsti Tiihonen ,  Marta Korczynska ,  Wouter Herman Noordman

    发明人： Nina Rautonen ,  Heli Putaala ,  Arthur Ouwehand ,  Kirsti Tiihonen ,  Marta Korczynska ,  Wouter Herman Noordman

    IPC分类号： A61K35/74

    CPC分类号： A61K35/747 ,  A23K10/18 ,  A23K50/40 ,  A23K50/75 ,  A23L33/135 ,  A23L33/30 ,  A61K35/745

    摘要： Use of at least one strain of a microorganism and/or a metabolite thereof in the manufacture of a support for administration to a subject for modulating satiety signalling, wherein the support is a pharmaceutically acceptable support or a food product. Suitably, the at least one strain of a microorganism and/or a metabolite thereof may be administered to the subject for the treatment and/or prevention of excess weight and/or a disease caused by excess weight. Likewise, the at least one strain of a microorganism and/or a metabolite thereof is administered to the subject for the treatment and/or prevention of obesity and/or a caused by obesity. Preferably, the microorganism is a probiotic microorganism. Suitably the microorganism may be a lactic acid bacterium. Li one embodiment the microorganism is a strain of Lactobacillus spp. and/or Bifidobacterium spp., for example a strain of Lactobacillus acidophilus, L. curvatus, L. salivarius and/or B. lactis.

    摘要翻译： 至少一种微生物菌株和/或其代谢产物在制备用于施用受试者以调节饱腹感信号的载体中的用途，其中所述载体是药学上可接受的载体或食品。 适当地，将微生物和/或其代谢物的至少一种菌株施用于受试者以治疗和/或预防超重和/或由超重引起的疾病。 同样，将微生物和/或其代谢物的至少一种菌株施用于受试者，用于治疗和/或预防肥胖症和/或由肥胖引起的肥胖症。 优选地，微生物是益生菌微生物。 适当地，微生物可以是乳酸菌。 李一个实例是微生物是一种乳杆菌属菌株。 和/或双歧杆菌属，例如嗜酸乳杆菌，弯曲曲霉，唾液乳杆菌和/或乳酸乳杆菌的菌株。

    Use
    10.
    发明申请
    Use 有权
    使用

    公开(公告)号：US20100061967A1

    公开(公告)日：2010-03-11

    申请号：US12162160

    申请日：2007-01-28

    申请人： Nina Rautonen

    发明人： Nina Rautonen

    IPC分类号： A61K35/74 ,  C12N1/20 ,  C12Q1/02

    CPC分类号： A61K35/747 ,  A23K10/18 ,  A23K50/40 ,  A23K50/75 ,  A23L33/135 ,  A23L33/30 ,  A61K35/745

    摘要： Use of at least one strain of a microorganism and/or a metabolite thereof in the manufacture of a support for administration to a subject for modulating satiety signalling, wherein the support is a pharmaceutically acceptable support or a food product. Suitably, the at least one strain of a microorganism and/or a metabolite thereof may be administered to the subject for the treatment and/or prevention of excess weight and/or a disease caused by excess weight. Likewise, the at least one strain of a microorganism and/or a metabolite thereof is administered to the subject for the treatment and/or prevention of obesity and/or a caused by obesity. Preferably, the microorganism is a probiotic microorganism. Suitably the microorganism may be a lactic acid bacterium. Li one embodiment the microorganism is a strain of Lactobacillus spp. and/or Bifidobacterium spp., for example a strain of Lactobacillus acidophilus, L. curvatus, L. salivarius and/or B. lactis.

    摘要翻译： 至少一种微生物菌株和/或其代谢物在制备用于施用受试者以调节饱腹感信号的载体中的用途，其中所述载体是药学上可接受的载体或食品。 适当地，可以向受试者施用至少一种微生物和/或其代谢物，用于治疗和/或预防由超重引起的过量和/或疾病。 同样，将微生物和/或其代谢物的至少一种菌株施用于受试者，用于治疗和/或预防肥胖症和/或由肥胖引起的肥胖症。 优选地，微生物是益生菌微生物。 适当地，微生物可以是乳酸菌。 李一个实例是微生物是一种乳杆菌属菌株。 和/或双歧杆菌属，例如嗜酸乳杆菌，弯曲曲霉，唾液乳杆菌和/或乳酸乳杆菌的菌株。